Metabolite comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
=== EC 1.14.21 With NADH or NADPH as one donor, and the other dehydrogenated === EC 1.14.21.1: Now EC 1.14.19.64, (S)-stylopine synthase EC 1.14.21.2: Now EC 1.14.19.65, (S)-cheilanthifoline synthase EC 1.14.21.3: Now EC 1.14.19.66, berbamunine synthase EC 1.14.21.4: Now EC 1.14.19.67, salutaridine synthase EC 1.14.21.5: Now EC 1.14.19.68, (S)-canadine synthase EC 1.14.21.6: Now EC 1.14.19.20, Δ7-sterol 5(6)-desaturase EC 1.14.21.7: Now EC 1.14.19.69, biflaviolin synthase EC 1.14.21.8: Now EC 1.14.19.63, pseudobaptigenin synthase EC 1.14.21.9: Now EC 1.14.19.70, mycocyclosin synthase * EC 1.14.21.10: Now EC 1.14.19.71, fumitremorgin C synthase * EC 1.14.21.11: Now EC 1.14.19.72, (–)-pluviatolide synthase * EC 1.14.21.12: Now EC 1.14.19.73, (S)-nandinine synthase *
== Characteristics == The average size of the orifice is 0.3 to 0.4 mm in diameter. There can be two or more foramina separated by a portion of dentin and cementum or by cementum only. If more than one foramen is present on each root, the largest one is designated as the apical foramen and the rest are considered accessory foramina.
In enzymology, creatinase (EC 3.5.3.3), also known as creatine amidinohydrolase, is classified as a hydrolase enzyme, acting on carbon-nitrogen bonds in linear amidines. Specifically, this enzyme breaks the amidino C-N bond in creatine, producing sarcosine and urea. Creatinase activity has been described in several bacteria species, most notably Pseudomonas putida, where the enzyme plays a key role in the metabolism of creatine as a nitrogen and carbon source.
Sources: en.wikipedia.org
Wanted immunogenicity typically relates to vaccines, where the injection of an antigen (the vaccine) provokes an immune response against the pathogen, protecting the organism from future exposure. Immunogenicity is a central aspect of vaccine development. Unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug-antibodies (ADAs), inactivating the therapeutic effects of the treatment and potentially inducing adverse effects. A challenge in biotherapy is predicting the immunogenic potential of novel protein therapeutics. For example, immunogenicity data from high-income countries are not always transferable to low-income and middle-income countries. Another challenge is considering how the immunogenicity of vaccines changes with age. Therefore, as stated by the World Health Organization, immunogenicity should be investigated in a target population since animal testing and in vitro models cannot precisely predict immune response in humans. Antigenicity is the capacity of a chemical structure (either an antigen or hapten) to bind specifically with a group of certain products that have adaptive immunity: T cell receptors or antibodies (a.k.a. B cell receptors). Antigenicity was more commonly used in the past to refer to what is now known as immunogenicity, and the two terms are still often used interchangeably. However, strictly speaking, immunogenicity refers to the ability of an antigen to induce an adaptive immune response.
=== Detection === This tag can also be used in detection of the protein via anti-biotin antibodies or avidin/streptavidin-tagged detection strategies such as enzyme reporters (e.g., horseradish peroxidase, alkaline phosphatase) or fluorescent probes. This can be useful in localization by fluorescent or electron microscopy, ELISA assays, ELISPOT assays, western blots and other immunoanalytical methods. Detection with monovalent streptavidin can avoid clustering or aggregation of the biotinylated target.
=== GABA === At GABAergic synapses, the cycle is called the GABA-glutamine cycle. Here the glutamine taken up by neurons is converted to glutamate, which is then metabolized into GABA by glutamate decarboxylase (GAD). Upon release, GABA is taken up into astrocytes via GABA transporters and then catabolized into succinate by the joint actions of GABA transaminase and succinate-semialdehyde dehydrogenase. Glutamine is synthesized from succinate via the TCA cycle, which includes a condensation reaction of oxaloacetate and acetyl-CoA-forming citrate. Then the synthesis of α-ketoglutarate and glutamate occurs, after which glutamate is again metabolized into GABA by GAD. The supply of glutamine to GABAergic neurons is less significant, because these neurons exhibit a larger proportion of reuptake of the released neurotransmitter compared to their glutamatergic counterparts
Many such committees were established in schools and colleges, where they were responsible for vetting staff, courses, and textbooks to determine if they were compatible with the country's revolutionary ideology. The People's Committees led to a high percentage of public involvement in decision making, within the limits permitted by the RCC, but exacerbated tribal divisions and tensions. They also served as a surveillance system, aiding the security services in locating individuals with views critical of the RCC, leading to the arrest of Ba'athists, Marxists, and Islamists. Operating in a pyramid structure, the base form of these Committees were local working groups, who sent elected representatives to the district level, and from there to the national level, divided between the General People's Congress and the General People's Committee. Above these remained Gaddafi and the RCC, who remained responsible for all major decisions. In crossing regional and tribal identities, the committee system aided national integration and centralization and tightened Gaddafi's control over the state and administrative apparatus.
Sources: en.wikipedia.org
== History == Biocon was formed in 1978 as Biocon India Private Limited, an India-based partner to the existing Irish multinational brewing enzyme producer Biocon Biochemicals Ltd., with US$10,000 as startup capital from Mazumdar-Shaw. The subsidiary initially produced enzymes for the brewing market such as the papaya enzyme papain and the fish collagen extract Iisinglass, a clarifying agent used for some beers and wines. In 1979, Biocon became the first Indian company to manufacture and export enzymes to the US and Europe, and spent the 1980s producing an increasing share of pharmaceuticals for the domestic market.
=== Transcriptional dysregulation === CREB-binding protein (CBP), a transcriptional coregulator, is essential for cell function because as a coactivator at a significant number of promoters, it activates the transcription of genes for survival pathways. CBP contains an acetyltransferase domain to which HTT binds through its polyglutamine-containing domain. Autopsied brains of those who had Huntington's disease also have been found to have incredibly reduced amounts of CBP. In addition, when CBP is overexpressed, polyglutamine-induced death is diminished, further demonstrating that CBP plays an important role in Huntington's disease and neurons in general.
Numerous Jamaicans migrated mainly to the islands of San Andres and Providencia. A number of other Europeans and North Americans migrated to the country in the late 19th and early 20th centuries, including people from the former USSR during and after the Second World War. Many immigrant communities have settled on the Caribbean coast, in particular recent immigrants from the Middle East and Europe. Barranquilla (the largest city of the Colombian Caribbean) and other Caribbean cities have the largest populations of Lebanese, Palestinian, and other Levantines. There are also important communities of Romanis and Jews. There is a major migration trend of Venezuelans, due to the political and economic situation in Venezuela. In August 2019, Colombia offered citizenship to more than 24,000 children of Venezuelan refugees who were born in Colombia.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.